Lineage Cell Therapeutics, Inc. Public Float
Lineage Cell Therapeutics, Inc. (LCTX) had Public Float of $161.50 million as of 2025-06-30, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-03-05
- 2025-06-30: Entity Public Float $161.50M.
- 2024-06-28: Entity Public Float $146.30M.
- 2023-06-30: Entity Public Float $185.60M.
- 2022-06-30: Entity Public Float $200.60M.
| Period end | Entity Public Float |
|---|---|
| 2025-06-30 | $161.50M 10-K · filed 2026-03-05 |
| 2024-06-28 | $146.30M 10-K · filed 2025-03-10 |
| 2023-06-30 | $185.60M 10-K · filed 2024-03-07 |
| 2022-06-30 | $200.60M 10-K/A · filed 2023-04-27 |
| 2021-06-30 | $356.80M 10-K · filed 2022-03-10 |
| 2020-06-30 | $93.90M 10-K · filed 2021-03-11 |
| 2019-06-28 | $118.60M 10-K · filed 2020-03-12 |
| 2018-06-30 | $176.70B 10-K · filed 2019-03-14 |
| 2017-06-30 | $223.15M 10-K · filed 2018-03-15 |
| 2016-06-30 | $165.29M 10-K · filed 2017-03-16 |
| 2015-06-30 | $165.57M 10-K · filed 2016-03-15 |
| 2014-06-30 | $120.38M 10-K · filed 2015-03-11 |
| 2013-06-30 | $135.80M 10-K · filed 2014-03-17 |
| 2012-06-30 | $121.65M 10-K · filed 2013-03-18 |
| 2011-06-30 | $126.42M 10-K · filed 2012-03-14 |
| 2010-06-30 | $123.74M 10-Q · filed 2011-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |